Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Habib Habib, MD, Saint Michael's Medical Center
ClinicalTrials.gov Identifier:
NCT01609569
First received: May 29, 2012
Last updated: February 20, 2013
Last verified: February 2013

May 29, 2012
February 20, 2013
May 2012
April 2014   (final data collection date for primary outcome measure)
Pro-calcitonin blood level [ Time Frame: "0,24 hours post cardiac intervention" ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01609569 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.
Utility of Pro-calcitonin as an Indicator of Ischemia in Patients Undergoing Percutaneous Coronary Intervention With Subsequent Coronary Complications.

The aim of this study is to determine on preliminary basis weather an elevated pro-calcitonin level can be used to assess ischemia as a result of coronary artery complications during percutaneous coronary intervention (PCI).

Pro-calcitonin is a type of protein found in the blood. This protein has recently be found to be elevated in patients with diseases of the arteries of the heart such as heart attack.

Percutaneous coronary intervention (PCI) is widely used in the treatment of many patients with blockage in the arteries of the heart.

the investigators normally used a marker called troponin after cardiac catheterization. However, this marker may not be specific.

Pro-calcitonin has been found to be a useful marker for the detection of myocardial injury. the value of Pro-calcitonin as a marker for the identification of myocardial damage undergoing PCI has not yet been studied.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Community sample

Coronary Disease
Not Provided
coronary complication

patients with coronary complication and patients without coronary complications.

pro-calcitonin will be measured in both groups to see if any correlation.

Sinning CR, Sinning JM, Schulz A, Schnabel RB, Lubos E, Wild PS, Papassotiriou J, Bergmann A, Blankenberg S, Munzel T, Bickel C; AtheroGene Study Investigators. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J. 2011;75(5):1184-91. Epub 2011 Mar 3.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
May 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients older than 18 years old.

Exclusion Criteria:

  • no consent.
  • suspicion of sepsis.
  • Patients with elevated troponin or procalcitonin before enrollment.
  • patients who had non-elective angioplasty (e.g. rescue angioplasty, primary angioplasty, salvage angioplasty, or emergency angioplasty)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01609569
#09/12
No
Habib Habib, MD, Saint Michael's Medical Center
Saint Michael's Medical Center
Not Provided
Principal Investigator: Habib Habib, MD Saint Michael's Medical Center
Study Director: Fayez Shamoon, MD,FACC Saint Michael's Medical Center
Study Chair: yaser elnhar, MD Saint Michael's Medical Center
Study Chair: Vincent Debari, PhD Saint Michael's Medical Center
Study Chair: Ashraf Jmeian, MD Saint Michael's Medical Center
Study Chair: Ahmad Isbitan, MD Saint Michael's Medical Center
Saint Michael's Medical Center
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP